[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$fHO7XLPWtoWjFFH9ortTF4_lpiTiCNULvMC7XECXcIrs":8,"$fBavu5NOpm1BmDlLLz3mvuhh9nykf1o05GYXlPozML6E":55,"$fkxoLmS1QxVqUaPI7h5Qf3MoK24h3oB45Rl8rnxlPe5I":59},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":54},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"hospital":17,"department":18,"postsTitle":19,"materialTotal":20,"videoTotal":21,"isConcern":7,"title":22,"coverVertical":23,"coverAcross":24,"content":25,"description":26,"views":27,"likes":21,"isThumbsUp":7,"isCollection":7,"collections":21,"createTime":28,"seoTitle":22,"seoKeywords":29,"seoDescription":30,"shelvesTime":31,"version":32,"menus":33,"menuId":35,"type":42,"quality":53,"commentCount":21,"isComment":42},61675,867327,[],"https://ystcdn.venuertc.com/medical/ystApp/aX219Ux3VMzNYuVkxtqA23OztnXHMduJ.png","何锦霞","嵊州市人民医院","血液内科","副主任医师",9,0,"弥漫大B细胞淋巴瘤三期Non-GCB型治疗常用化疗药品用药指南","","https://ystcdn.venuertc.com/venue/AI/0065faf1-60fa-4530-ab06-2cc84caf0b40.jpg","\u003Cdiv id=\"material_title\">\n  \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">弥漫大B细胞淋巴瘤三期Non-GCB型治疗常用化疗药品用药指南\u003C/h2>\n\u003C/div>\n\n\u003Cdiv class=\"custom-section\">\n  \u003Cdiv class=\"custom-header-bg\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">化疗联合用药：正确打开方式，从安全起步\u003C/h2>\n  \u003C/div>\n  \u003Cp>化疗药物在淋巴瘤的治疗中经常需要联合应用，形成足够的攻击力。这类药品大多通过影响肿瘤细胞的分裂或免疫应答来发挥作用。对此类组合，我们要关注它们的主要成分、如何使用，以及每一步的用药安全细节。下面，围绕7个要点，帮你梳理常见药物（如环磷酰胺、阿霉素、多柔比星、长春新碱、利妥昔单抗等）的正确使用方式，以及联合用药时容易被忽视的细节。\u003C/p>\n\u003C/div>\n\n\u003Cdiv class=\"custom-section\">\n  \u003Cdiv class=\"custom-header-bg\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">01 🚩 常见成分与剂型：组合有讲究\u003C/h2>\n  \u003C/div>\n  \u003Cul>\n    \u003Cli>\u003Cstrong>环磷酰胺（Cyclophosphamide）\u003C/strong> 通常以注射剂形式出现，偶有口服片剂；为细胞毒性烷化剂之一。\u003C/li>\n    \u003Cli>\u003Cstrong>多柔比星/阿霉素（Doxorubicin/Adriamycin）\u003C/strong> 常见为注射用粉剂，需溶解配制后静脉注射。\u003C/li>\n    \u003Cli>\u003Cstrong>长春新碱（Vincristine）\u003C/strong> 主要为注射液，绝不能口服，也不能作鞘内注射。\u003C/li>\n    \u003Cli>\u003Cstrong>利妥昔单抗（Rituximab）\u003C/strong> 为单克隆抗体类药物，剂型为静脉滴注浓溶液。\u003C/li>\n    \u003Cli>\u003Cstrong>泼尼松/泼尼松龙（Prednisone/Prednisolone）\u003C/strong> 通常为口服片剂。\u003C/li>\n  \u003C/ul>\n  \u003Cp>组合用药必须遵循医嘱，每种药品的配伍和剂量都严格限定。\u003C/p>\n\u003C/div>\n\n\u003Cdiv class=\"custom-section\">\n  \u003Cdiv class=\"custom-header-bg\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">02 ⏱ 化疗药物的作用机制简析\u003C/h2>\n  \u003C/div>\n  \u003Cul>\n    \u003Cli>\u003Cstrong>环磷酰胺\u003C/strong>：通过烷化DNA，阻断肿瘤细胞分裂。\u003C/li>\n    \u003Cli>\u003Cstrong>多柔比星/阿霉素\u003C/strong>：插入DNA双链，干扰DNA的复制。\u003C/li>\n    \u003Cli>\u003Cstrong>长春新碱\u003C/strong>：抑制微管蛋白，阻止细胞有丝分裂。\u003C/li>\n    \u003Cli>\u003Cstrong>利妥昔单抗\u003C/strong>：靶向肿瘤B细胞表面的CD20抗原，启动免疫杀伤。\u003C/li>\n    \u003Cli>\u003Cstrong>泼尼松/泼尼松龙\u003C/strong>：为糖皮质激素，减少炎症并抑制免疫反应。\u003C/li>\n  \u003C/ul>\n  \u003Cp>这些机制决定了联合用药的协同效应，能从多个环节干预异常细胞。\u003C/p>\n\u003C/div>\n\n\u003Cdiv class=\"custom-section\">\n  \u003Cdiv class=\"custom-header-bg\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">03 💊 服用方法与用药顺序\u003C/h2>\n  \u003C/div>\n  \u003Cul>\n    \u003Cli>\u003Cstrong>利妥昔单抗\u003C/strong>：通常在一天的所有药物中最先滴注。开始前会给予抗过敏药物预防反应。输注速度从慢到快逐步增加。\u003C/li>\n    \u003Cli>\u003Cstrong>环磷酰胺、多柔比星、长春新碱\u003C/strong>：均为静脉给药，具体顺序依方案制定，切勿自行调整。\u003C/li>\n    \u003Cli>\u003Cstrong>泼尼松/泼尼松龙\u003C/strong>：一般口服，建议在早餐后服用，可减少胃部刺激。\u003C/li>\n  \u003C/ul>\n  \u003Cp>正确做法：遵循医院设置的用药次序，不随意更改单独药物的时间或途径。\u003C/p>\n\u003C/div>\n\n\u003Cdiv class=\"custom-section\">\n  \u003Cdiv class=\"custom-header-bg\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">04 💡 药物相互作用：联合不是简单叠加\u003C/h2>\n  \u003C/div>\n  \u003Cul>\n    \u003Cli>\u003Cstrong>长春新碱与其他神经毒性药物\u003C/strong>：如果与某些癌症化疗药联用，可能增强神经损害风险。\u003C/li>\n    \u003Cli>\u003Cstrong>环磷酰胺与酶诱导药物（如苯巴比妥）\u003C/strong>：可能影响其体内活性和毒性。\u003C/li>\n    \u003Cli>\u003Cstrong>利妥昔单抗与生物制剂、疫苗\u003C/strong>：与活疫苗同时使用不安全，需提前告知医生。\u003C/li>\n    \u003Cli>\u003Cstrong>泼尼松与抗真菌药、某些抗生素\u003C/strong>：有时会干扰代谢，影响药效。\u003C/li>\n  \u003C/ul>\n  \u003Cp>联合用药期间，必须避免自行加用中药、保健品或其他处方药，任何新增药物都要先与主治医生确认。\u003C/p>\n\u003C/div>\n\n\u003Cdiv class=\"custom-section\">\n  \u003Cdiv class=\"custom-header-bg\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">05 👩‍⚕️ 特殊人群用药注意事项\u003C/h2>\n  \u003C/div>\n  \u003Cul>\n    \u003Cli>\u003Cstrong>老年患者\u003C/strong>：药物代谢减慢，部分药品可能需要降低剂量，密切观察副反应。\u003C/li>\n    \u003Cli>\u003Cstrong>肝、肾功能不全者\u003C/strong>：尤需调整环磷酰胺、阿霉素以及长春新碱剂量，预防毒副反应。\u003C/li>\n    \u003Cli>\u003Cstrong>孕妇及哺乳期女性\u003C/strong>：化疗药物多为禁忌，绝大多数组合不能使用，务必提前报备。\u003C/li>\n    \u003Cli>\u003Cstrong>儿童患者\u003C/strong>：需按体表面积或体重精准计算剂量，不能按照成人方案机械换算。\u003C/li>\n  \u003C/ul>\n  \u003Cp>正确做法：如为特殊人群，请务必主动向医护团队提供详细病史与身体状况信息。\u003C/p>\n\u003C/div>\n\n\u003Cdiv class=\"custom-section\">\n  \u003Cdiv class=\"custom-header-bg\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">06 ⚠️ 不良反应及处理办法\u003C/h2>\n  \u003C/div>\n  \u003Cul>\n    \u003Cli>\u003Cstrong>环磷酰胺\u003C/strong>：常见恶心、呕吐、白细胞减少，长期可能引发膀胱刺激。如出现血尿应立刻就医。\u003C/li>\n    \u003Cli>\u003Cstrong>多柔比星/阿霉素\u003C/strong>：心脏毒性为其典型副作用，临床多会监测心功能。\u003C/li>\n    \u003Cli>\u003Cstrong>长春新碱\u003C/strong>：有引发周围神经损害的风险，如手足麻木、运动障碍等。\u003C/li>\n    \u003Cli>\u003Cstrong>利妥昔单抗\u003C/strong>：首剂易诱发输液反应，如发热、寒战、皮疹。必须在有监护条件下首用。\u003C/li>\n    \u003Cli>\u003Cstrong>泼尼松/泼尼松龙\u003C/strong>：可引起血糖升高、胃肠不适、情绪波动。\u003C/li>\n  \u003C/ul>\n  \u003Cp>需要注意：任何不适症状，都需第一时间告知医护，严禁擅自停药或调整治疗方案。\u003C/p>\n\u003C/div>\n\n\u003Cdiv class=\"custom-section\">\n  \u003Cdiv class=\"custom-header-bg\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">07 📅 正确的用药周期与漏服/过量处理\u003C/h2>\n  \u003C/div>\n  \u003Cul>\n    \u003Cli>\u003Cstrong>用药周期\u003C/strong>：每一轮联合用药通常间隔21天左右，期间间歇详细评估身体状况。\u003C/li>\n    \u003Cli>\u003Cstrong>漏服口服泼尼松\u003C/strong>：若刚发现，尽快补服。若快到下次服药时间，跳过，不要重复用量。\u003C/li>\n    \u003Cli>\u003Cstrong>过量风险\u003C/strong>：无论注射药品或口服制剂，过量均可能引发严重的毒副反应，必须立刻前往医院急诊处理。\u003C/li>\n  \u003C/ul>\n  \u003Cp>建议：手机设提醒、用药日历、家人协助，都是防止漏服的实用方法。重要剂量必须严格记录，尤其是在家庭自行服用阶段。\u003C/p>\n\u003C/div>\n\n\u003Cdiv class=\"custom-section\">\n  \u003Cdiv class=\"custom-header-bg\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">08 🗃️ 储存与药品有效期管理\u003C/h2>\n  \u003C/div>\n  \u003Cul>\n    \u003Cli>\u003Cstrong>注射剂\u003C/strong>：医院统一保存与配置，患者无需在家自主贡存。\u003C/li>\n    \u003Cli>\u003Cstrong>口服泼尼松/泼尼松龙\u003C/strong>：避光、干燥室温（15-25℃）保存。药瓶盖好，远离儿童与宠物。\u003C/li>\n    \u003Cli>\u003Cstrong>利妥昔单抗\u003C/strong>：如需短时存放，原包装冷藏于2-8℃，切勿冷冻。\u003C/li>\n    \u003Cli>\u003Cstrong>有效期\u003C/strong>：过期化疗药物不可使用，剩余药物按医院或药店规范回收处理。\u003C/li>\n  \u003C/ul>\n  \u003Cp>正确做法：定期检查药品外观和保质期，发现瓶体变色、结块、异味则要废弃。\u003C/p>\n\u003C/div>\n\n\u003Cdiv class=\"custom-section\">\n  \u003Cdiv class=\"custom-header-bg\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">09 🏥 用药案例参考\u003C/h2>\n  \u003C/div>\n  \u003Cul>\n    \u003Cli>在临床中，有位女性患者因联合使用环磷酰胺、多柔比星、长春新碱与利妥昔单抗，首剂输液时出现了寒战和轻度皮疹，及时减慢输注速度并加强监护后顺利度过。\u003C/li>\n    \u003Cli>有患者在家口服泼尼松时，因漏服剂量，合理补服并做好记录，后续未见明显不良反应。\u003C/li>\n    \u003Cli>在某一次化疗周期结束后，一位老年患者出现手足麻木，经评估为与长春新碱相关，调整剂量并辅以对症处理后症状好转。\u003C/li>\n  \u003C/ul>\n  \u003Cp>这些实例提示，主动沟通和充分知晓副反应，有助于最大程度保障安全用药。\u003C/p>\n\u003C/div>\n\n\u003Cdiv class=\"custom-section\">\n  \u003Cdiv class=\"custom-header-bg\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">10 ✨ 使用总结与用药提示\u003C/h2>\n  \u003C/div>\n  \u003Cul>\n    \u003Cli>化疗用药不是简单的叠加，每种药物都有严格的适应症、用法、禁忌和观察要点。\u003C/li>\n    \u003Cli>组合疗程强调顺序、剂量和定期评估，切忌随意加减或自行停药。\u003C/li>\n    \u003Cli>应对不良反应最有效的办法是主动上报和协助医生调整。\u003C/li>\n    \u003Cli>家中保存药品需规范，过期或变质药切勿服用。\u003C/li>\n    \u003Cli>安全、合法渠道购药，勿信偏方、以防假药风险。\u003C/li>\n  \u003C/ul>\n  \u003Cp>正确用药，每一步都至关重要。遇到任何不明情况，要及时和医生、药师沟通，做到知药、懂药、用对药。\u003C/p>\n\u003C/div>\n\n\u003Cdiv class=\"custom-section\">\n  \u003Cdiv class=\"custom-header-bg\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">主要参考文献\u003C/h2>\n  \u003C/div>\n  \u003Col>\n    \u003Cli>Coiffier, B. et al. (2002). CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma. The New England Journal of Medicine, 346(4), 235-242.\u003C/li>\n    \u003Cli>Pfreundschuh, M. et al. (2006). Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). The Lancet Oncology, 7, 379-391.\u003C/li>\n    \u003Cli>Younes, A., & Sehn, L. H. (2017). Novel agents in the treatment of diffuse large B-cell lymphoma: A review. Hematology/Oncology Clinics, 31(1), 105–123.\u003C/li>\n    \u003Cli>National Comprehensive Cancer Network (NCCN) Guidelines: B-Cell Lymphomas. (2023). NCCN Clinical Practice Guidelines in Oncology. Version 5.2023.\u003C/li>\n    \u003Cli>Kümler, T. et al. (2014). Neurological complications of chemotherapy with special focus on the vinca alkaloids. Expert Opinion on Drug Metabolism & Toxicology, 10(5), 721–729.\u003C/li>\n  \u003C/ol>\n\u003C/div>\n\n\u003Cstyle>\n/* 独立样式名，避免全局样式冲突 */\n#material_title {\n  background-color: #f5f8fa;\n  text-align: center;\n  padding: 30px 0 15px 0;\n  margin-bottom: 20px;\n  border-radius: 12px;\n  box-shadow: 0 2px 8px rgba(100,120,140,0.07);\n}\n#material_title h1 {\n  font-size: 2.2em;\n  color: #3672b0;\n  margin: 0;\n  font-weight: 700;\n  letter-spacing: 1px;\n}\n\n.custom-section {\n  margin: 18px auto 22px auto;\n  max-width: 820px;\n  background: #fff;\n  border-radius: 10px;\n  box-shadow: 0 1px 6px rgba(70,120,140,0.10);\n  padding: 32px 22px 28px 22px;\n}\n\n.custom-header-bg {\n  background: linear-gradient(90deg, #e3effb 0%, #fbfcfe 100%);\n  border-left: 8px solid #b6d0ed;\n  border-radius: 7px 7px 7px 7px;\n  margin-bottom: 23px;\n  padding: 11px 0 10px 24px;\n  min-height: 40px;\n  display: flex;\n  align-items: center;\n}\n.custom-header-bg h2 {\n  margin: 0;\n  color: #165a92;\n  font-size: 1.38em;\n  font-weight: 600;\n  letter-spacing: 0.8px;\n}\n\n.custom-section ul {\n  margin: 12px 0 18px 24px;\n  padding: 0;\n}\n.custom-section ul li {\n  font-size: 1.04em;\n  margin-bottom: 8px;\n  color: #223652;\n  line-height: 1.7;\n}\n\n.custom-section p {\n  color: #374151;\n  font-size: 1.08em;\n  line-height: 1.75;\n  text-indent: 2em;\n  margin-top: 10px;\n  margin-bottom: 10px;\n}\n\n.custom-section ol {\n  margin: 14px 0 0 28px;\n  padding: 0;\n  color: #374151;\n  font-size: 1.06em;\n  line-height: 1.8;\n}\n\n@media (max-width: 520px) {\n  .custom-section {\n    padding: 15px 2vw 13px 2vw;\n    max-width: 97vw;\n  }\n  #material_title {\n    padding: 16px 0 10px 0;\n  }\n  .custom-header-bg {\n    border-left-width: 4px;\n    min-height: 34px;\n    padding-left: 8px;\n  }\n}\n\u003C/style>\n","\u003Cdiv id=\"material_title\">\n  \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight:",449,"2025-08-21 14:00:48","弥漫大B细胞淋巴瘤, 化疗药物, 利妥昔单抗, 环磷酰胺, 多柔比星, 用药安全, 不良反应, 患者指南","深入了解弥漫大B细胞淋巴瘤治疗中的化疗药物使用指南，助力患者和医务人员有效应对药物组合和安全用药问题。本文详尽说明药物作用、使用方法及应对不良反应。","2025-08-22 22:24:00",2,[34],{"menuId":35,"menuName":36,"parentId":21,"orderNum":32,"path":37,"component":38,"isFrame":39,"isCache":40,"menuType":41,"visible":42,"status":21,"createDept":6,"remark":23,"createTime":43,"children":44,"columnImage":45,"columnLogo":46,"uncheckedLogo":6,"checkedLogo":6,"isHot":42,"isHome":21,"forceLogin":21,"color":47,"seoTitle":48,"seoKeywords":49,"seoDescription":50,"contentNum":6,"promotionalPoster":51,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":52,"routerPath":37,"componentInfo":38},"1986713082609147906","健康科普","article","/article.html","1","0","T",1,"2025-11-07 16:31:25",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:49/d4291d16-ed1c-48dd-84c8-ec1f85980b75.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:52/6fe64094-9416-442c-a66d-032fb292666a.png","#c8e6ca","健康科普助力健康中国2030:共享健康知识新理念","健康科普, 健康中国, 科普知识, 健康家庭, 性健康, 营养健康, 运动健康, 科普宣传","探索健康科普在健康中国行动中的重要角色,了解最新的健康科普创新大赛、动漫及短视频,传播健康知识,助力全民健康。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:56/bd33f471-6c54-4d1b-a364-b06973dbc144.png","Article","癌症肿瘤,重大疾病",true,{"code":9,"msg":10,"message":6,"data":56,"success":54},{"pageNo":42,"pageSize":57,"result":58,"totalSize":21},10,[],{"code":9,"msg":10,"message":6,"data":60,"success":54},{"authors":61,"appraiseDimensionScoresVos":62},[],[]]